HC Wainwright Issues Pessimistic Estimate for VERA Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities researchers at HC Wainwright reduced their Q2 2025 earnings per share estimates for shares of Vera Therapeutics in a research note issued on Wednesday, May 7th. HC Wainwright analyst A. He now expects that the company will earn ($0.90) per share for the quarter, down from their prior forecast of ($0.81). HC Wainwright has a "Buy" rating and a $75.00 price objective on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics' Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($3.42) EPS, Q1 2026 earnings at ($0.78) EPS, Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($2.51) EPS.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same quarter in the previous year, the business earned ($0.56) earnings per share.

A number of other analysts also recently issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price objective for the company. Guggenheim boosted their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Wolfe Research assumed coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective for the company. Wedbush cut their price objective on shares of Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Finally, Cantor Fitzgerald cut their price objective on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $63.33.

Vera Therapeutics Stock Performance

NASDAQ VERA traded down $0.29 during trading on Friday, reaching $21.29. The company's stock had a trading volume of 213,327 shares, compared to its average volume of 775,437. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -8.16 and a beta of 1.28. Vera Therapeutics has a 12 month low of $18.53 and a 12 month high of $51.61. The firm has a 50 day moving average price of $23.92 and a 200 day moving average price of $34.43.

Hedge Funds Weigh In On Vera Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in VERA. Barclays PLC lifted its position in shares of Vera Therapeutics by 94.1% during the 3rd quarter. Barclays PLC now owns 85,395 shares of the company's stock worth $3,774,000 after buying an additional 41,394 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Vera Therapeutics by 116.7% during the 4th quarter. SG Americas Securities LLC now owns 20,270 shares of the company's stock worth $857,000 after buying an additional 10,916 shares during the last quarter. KBC Group NV lifted its position in shares of Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after buying an additional 1,387 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Vera Therapeutics by 27.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,427 shares of the company's stock worth $568,000 after purchasing an additional 2,882 shares in the last quarter. Finally, Jennison Associates LLC increased its position in Vera Therapeutics by 82.0% during the 4th quarter. Jennison Associates LLC now owns 813,861 shares of the company's stock worth $34,418,000 after purchasing an additional 366,763 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.